铅笔束质子治疗前列腺癌使用直肠间隔器无直肠内气囊。

IF 2.1 Q3 ONCOLOGY International Journal of Particle Therapy Pub Date : 2022-04-06 eCollection Date: 2022-01-01 DOI:10.14338/IJPT-21-00039
Matthew Forsthoefel, Ryan Hankins, Elizabeth Ballew, Cara Frame, David DeBlois, Dalong Pang, Pranay Krishnan, Keith Unger, Keith Kowalczyk, John Lynch, Anatoly Dritschilo, Sean P Collins, Jonathan W Lischalk
{"title":"铅笔束质子治疗前列腺癌使用直肠间隔器无直肠内气囊。","authors":"Matthew Forsthoefel,&nbsp;Ryan Hankins,&nbsp;Elizabeth Ballew,&nbsp;Cara Frame,&nbsp;David DeBlois,&nbsp;Dalong Pang,&nbsp;Pranay Krishnan,&nbsp;Keith Unger,&nbsp;Keith Kowalczyk,&nbsp;John Lynch,&nbsp;Anatoly Dritschilo,&nbsp;Sean P Collins,&nbsp;Jonathan W Lischalk","doi":"10.14338/IJPT-21-00039","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Proton beam radiotherapy (PBT) has been used for the definitive treatment of localized prostate cancer with low rates of high-grade toxicity and excellent patient-reported quality-of-life metrics. Technological advances such as pencil beam scanning (PBS), Monte Carlo dose calculations, and polyethylene glycol gel rectal spacers have optimized prostate proton therapy. Here, we report the early clinical outcomes of patients treated for localized prostate cancer using modern PBS-PBT with hydrogel rectal spacing and fiducial tracking without the use of endorectal balloons.</p><p><strong>Materials and methods: </strong>This is a single institutional review of consecutive patients treated with histologically confirmed localized prostate cancer. Prior to treatment, all patients underwent placement of fiducials into the prostate and insertion of a hydrogel rectal spacer. Patients were typically given a prescription dose of 7920 cGy at 180 cGy per fraction using a Monte Carlo dose calculation algorithm. Acute and late toxicity were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE), version 5. Biochemical failure was defined using the Phoenix definition.</p><p><strong>Results: </strong>From July 2018 to April 2020, 33 patients were treated (median age, 75 years). No severe acute toxicities were observed. The most common acute toxicity was urinary frequency. With a median follow-up of 18 months, there were no high-grade genitourinary late toxicities; however, one grade 3 gastrointestinal toxicity was observed. Late erectile dysfunction was common. One treatment failure was observed at 21 months in a patient treated for high-risk prostate cancer.</p><p><strong>Conclusion: </strong>Early clinical outcomes of patients treated with PBS-PBT using Monte Carlo-based planning, fiducial placement, and rectal spacers sans endorectal balloons demonstrate minimal treatment-related toxicity with good oncologic outcomes. Rectal spacer stabilization without the use of endorectal balloons is feasible for the use of PBS-PBT.</p>","PeriodicalId":36923,"journal":{"name":"International Journal of Particle Therapy","volume":"9 1","pages":"28-41"},"PeriodicalIF":2.1000,"publicationDate":"2022-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238133/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prostate Cancer Treatment with Pencil Beam Proton Therapy Using Rectal Spacers sans Endorectal Balloons.\",\"authors\":\"Matthew Forsthoefel,&nbsp;Ryan Hankins,&nbsp;Elizabeth Ballew,&nbsp;Cara Frame,&nbsp;David DeBlois,&nbsp;Dalong Pang,&nbsp;Pranay Krishnan,&nbsp;Keith Unger,&nbsp;Keith Kowalczyk,&nbsp;John Lynch,&nbsp;Anatoly Dritschilo,&nbsp;Sean P Collins,&nbsp;Jonathan W Lischalk\",\"doi\":\"10.14338/IJPT-21-00039\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Proton beam radiotherapy (PBT) has been used for the definitive treatment of localized prostate cancer with low rates of high-grade toxicity and excellent patient-reported quality-of-life metrics. Technological advances such as pencil beam scanning (PBS), Monte Carlo dose calculations, and polyethylene glycol gel rectal spacers have optimized prostate proton therapy. Here, we report the early clinical outcomes of patients treated for localized prostate cancer using modern PBS-PBT with hydrogel rectal spacing and fiducial tracking without the use of endorectal balloons.</p><p><strong>Materials and methods: </strong>This is a single institutional review of consecutive patients treated with histologically confirmed localized prostate cancer. Prior to treatment, all patients underwent placement of fiducials into the prostate and insertion of a hydrogel rectal spacer. Patients were typically given a prescription dose of 7920 cGy at 180 cGy per fraction using a Monte Carlo dose calculation algorithm. Acute and late toxicity were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE), version 5. Biochemical failure was defined using the Phoenix definition.</p><p><strong>Results: </strong>From July 2018 to April 2020, 33 patients were treated (median age, 75 years). No severe acute toxicities were observed. The most common acute toxicity was urinary frequency. With a median follow-up of 18 months, there were no high-grade genitourinary late toxicities; however, one grade 3 gastrointestinal toxicity was observed. Late erectile dysfunction was common. One treatment failure was observed at 21 months in a patient treated for high-risk prostate cancer.</p><p><strong>Conclusion: </strong>Early clinical outcomes of patients treated with PBS-PBT using Monte Carlo-based planning, fiducial placement, and rectal spacers sans endorectal balloons demonstrate minimal treatment-related toxicity with good oncologic outcomes. Rectal spacer stabilization without the use of endorectal balloons is feasible for the use of PBS-PBT.</p>\",\"PeriodicalId\":36923,\"journal\":{\"name\":\"International Journal of Particle Therapy\",\"volume\":\"9 1\",\"pages\":\"28-41\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2022-04-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238133/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Particle Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14338/IJPT-21-00039\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Particle Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14338/IJPT-21-00039","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:质子束放疗(PBT)已被用于局限性前列腺癌的最终治疗,具有低发生率的高毒性和优秀的患者报告的生活质量指标。技术进步,如铅笔束扫描(PBS),蒙特卡罗剂量计算,聚乙二醇凝胶直肠间隔器优化前列腺质子治疗。在这里,我们报告了使用现代PBS-PBT治疗局限性前列腺癌患者的早期临床结果,该技术具有水凝胶直肠间距和基准跟踪,而不使用直肠内球囊。材料和方法:这是一项对组织学证实的局限性前列腺癌患者连续治疗的单一机构综述。在治疗之前,所有患者都接受了将基准植入前列腺和插入水凝胶直肠垫片的治疗。使用蒙特卡洛剂量计算算法,患者通常给予处方剂量7920 cGy,每分数为180 cGy。使用不良事件通用术语标准(CTCAE)第5版评估急性和晚期毒性。使用Phoenix定义来定义生化失败。结果:2018年7月至2020年4月,33例患者接受治疗,中位年龄75岁。未见严重急性毒性反应。最常见的急性毒性是尿频。中位随访期为18个月,没有出现高度泌尿生殖系统晚期毒性;然而,观察到一个3级胃肠道毒性。晚期勃起功能障碍是常见的。在一名高风险前列腺癌患者治疗21个月时观察到治疗失败。结论:使用蒙特卡罗计划、基准放置和直肠间隔器治疗PBS-PBT患者的早期临床结果显示,治疗相关毒性最小,肿瘤预后良好。在使用PBS-PBT时,不使用直肠内气囊的直肠间隔物稳定是可行的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Prostate Cancer Treatment with Pencil Beam Proton Therapy Using Rectal Spacers sans Endorectal Balloons.

Purpose: Proton beam radiotherapy (PBT) has been used for the definitive treatment of localized prostate cancer with low rates of high-grade toxicity and excellent patient-reported quality-of-life metrics. Technological advances such as pencil beam scanning (PBS), Monte Carlo dose calculations, and polyethylene glycol gel rectal spacers have optimized prostate proton therapy. Here, we report the early clinical outcomes of patients treated for localized prostate cancer using modern PBS-PBT with hydrogel rectal spacing and fiducial tracking without the use of endorectal balloons.

Materials and methods: This is a single institutional review of consecutive patients treated with histologically confirmed localized prostate cancer. Prior to treatment, all patients underwent placement of fiducials into the prostate and insertion of a hydrogel rectal spacer. Patients were typically given a prescription dose of 7920 cGy at 180 cGy per fraction using a Monte Carlo dose calculation algorithm. Acute and late toxicity were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE), version 5. Biochemical failure was defined using the Phoenix definition.

Results: From July 2018 to April 2020, 33 patients were treated (median age, 75 years). No severe acute toxicities were observed. The most common acute toxicity was urinary frequency. With a median follow-up of 18 months, there were no high-grade genitourinary late toxicities; however, one grade 3 gastrointestinal toxicity was observed. Late erectile dysfunction was common. One treatment failure was observed at 21 months in a patient treated for high-risk prostate cancer.

Conclusion: Early clinical outcomes of patients treated with PBS-PBT using Monte Carlo-based planning, fiducial placement, and rectal spacers sans endorectal balloons demonstrate minimal treatment-related toxicity with good oncologic outcomes. Rectal spacer stabilization without the use of endorectal balloons is feasible for the use of PBS-PBT.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
International Journal of Particle Therapy
International Journal of Particle Therapy Medicine-Radiology, Nuclear Medicine and Imaging
CiteScore
3.70
自引率
5.90%
发文量
23
审稿时长
20 weeks
期刊最新文献
Impact of COVID-19 Pandemic on Carbon-Ion Radiation Therapy in Japan: A Japanese National Registry Study. Vaginal Mucosal Melanoma Cell Activation in Response to Photon or Carbon Ion Irradiation. Navigating a New Frontier: Evaluating Leadless Pacemakers in Proton Therapy. Cardiac Conduction System as an OAR in Radiation Therapy: Doses to SA/AV Nodes and Their Reduction. Value of Carbon-Ion Radiation Therapy for Breast Cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1